Literature DB >> 19924389

[Bleeding complications due to anticoagulatoric therapy].

R Mahnel1, S Bassus, C M Kirchmaier.   

Abstract

Anticoagulation is a standard treatment in patients with thrombosis and commonly used in surgical procedures for primary thrombosis prophylaxis. The occurrence of bleeding episodes is the predominant treatment complication. Although monitoring of hemostatic parameters reduces the risk of bleeding, bleedings occur in approximately 10% of patients. Besides standard life saving procedures it is crucial to ensure sufficient coagulation by administering factor concentrates (e.g. fresh frozen plasma, prothrombin complex, recombinant factor VIIa), platelet concentrates and fluid. Specific antidotes are not available for the majority of anticoagulant agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19924389     DOI: 10.1007/s00108-009-2520-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  14 in total

Review 1.  New anti-thrombotic agents: emphasis on hemorrhagic complications and their management.

Authors:  Heng Joo Ng; Mark A Crowther
Journal:  Semin Hematol       Date:  2006-01       Impact factor: 3.851

2.  [Clinical assessment of potential fields of application of recombinant factor VIIa in internal and pediatric diseases. Recommendations of an expert group].

Authors:  Carl-Erik Dempfle; Dietrich Gulba; Carl M Kirchmaier; Robert Klamroth; Wolfgang Korte; Reinhard Lorenz; Markus Peck-Radosavljevic; Alex Veldman; Rainer B Zotz
Journal:  Med Klin (Munich)       Date:  2007-01-15

3.  Guidelines on the management of massive blood loss.

Authors:  D Stainsby; S MacLennan; D Thomas; J Isaac; P J Hamilton
Journal:  Br J Haematol       Date:  2006-12       Impact factor: 6.998

4.  Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Hirsh; Gordon Guyatt; Gregory W Albers; Robert Harrington; Holger J Schünemann
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

5.  Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

Authors:  B E Lewis; D E Wallis; S D Berkowitz; W H Matthai; J Fareed; J M Walenga; J Bartholomew; R Sham; R G Lerner; Z R Zeigler; P K Rustagi; I K Jang; S D Rifkin; J Moran; M J Hursting; J G Kelton
Journal:  Circulation       Date:  2001-04-10       Impact factor: 29.690

Review 6.  Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms.

Authors:  F Dentali; W Ageno; M Crowther
Journal:  J Thromb Haemost       Date:  2006-09       Impact factor: 5.824

7.  Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy.

Authors:  M Makris; M Greaves; W S Phillips; S Kitchen; F R Rosendaal; E F Preston
Journal:  Thromb Haemost       Date:  1997-03       Impact factor: 5.249

Review 8.  Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Mark N Levine; Gary Raskob; Rebecca J Beyth; Clive Kearon; Sam Schulman
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

Review 9.  Epidemiology and management of bleeding in patients using vitamin K antagonists.

Authors:  M Levi
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

10.  Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.

Authors:  Harry R Büller; Bruce L Davidson; Hervé Decousus; Alexander Gallus; Michael Gent; Franco Piovella; Martin H Prins; Gary Raskob; Annelise E M Segers; Roger Cariou; Oscar Leeuwenkamp; Anthonie W A Lensing
Journal:  Ann Intern Med       Date:  2004-06-01       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.